Following her interview earlier in the year, Dr Jolanta Airey, Cynata CMO spoke to Stockhead about the chances of phase 3 clinical trial success, and Cynata’s own osteoarthritis trial. 

Read the story here: https://stockhead.com.au/health/the-chances-of-phase-3-success-and-the-asx-health-stocks-that-are-close-a-home-run/